Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | TERT | O14746 | 3/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | PPARG | P37231 | 3/20 | 0.50 |
| ▸ | PPARD | Q03181 | 3/20 | 0.50 |
| ▸ | PPARA | Q07869 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | FABP4 | P15090 | 2/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30000546 | 1.00 | FASN (0.61) | FASNALDH1A1TSHRFAAHKDM4E | |
| SCHEMBL1427212 | 1.00 | FASN (0.61) | FASNALDH1A1TSHRFAAHKDM4E | |
| SCHEMBL29253334 | 1.00 | FASN (0.61) | FASNALDH1A1TSHRFAAHKDM4E | |
| SCHEMBL1427215 | 1.00 | FASN (0.61) | FASNALDH1A1TSHRFAAHKDM4E | |
| SCHEMBL140063 | 1.00 | FASN (0.61) | FASNALDH1A1TSHRFAAHKDM4E | |
| SCHEMBL1039992 | 1.00 | FASN (0.61) | FASNALDH1A1TSHRFAAHKDM4E | |
| SCHEMBL140696 | 1.00 | FASN (0.61) | FASNALDH1A1TSHRFAAHKDM4E | |
| SCHEMBL2732862 | 1.00 | FASN (0.61) | FASNALDH1A1TSHRFAAHKDM4E | |
| SCHEMBL15048699 | 1.00 | FASN (0.61) | FASNALDH1A1TSHRFAAHKDM4E | |
| SCHEMBL28614760 | 1.00 | FASN (0.61) | FASNALDH1A1TSHRFAAHKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041696-A1 | IN-SITU PRODUCTION OF ANTI-INFLAMMATORY LIPIDS USING MILK FAT GLOBULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-12 | — | — | US | claimed |
| WO-2024229108-A1 | IN-SITU PRODUCTION OF ANTI-INFLAMMATORY LIPIDS USING MILK FAT GLOBULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-07 | — | — | WO | claimed |
| WO-2024065892-A1 | USE OF REAGENT FOR DETECTING EOSINOPHIL, EOSINOPHIL AND CYTOPLASM CONTENT THEREOF, AND HYDROXY DOCOSAHEXAENOIC ACID | 中国医学科学院基础医学研究所 | 2024-04-04 | — | — | WO | claimed |
| CN-115768873-A | Viable cell constructs for biosynthesizing dairy products, and products and methods related thereto | 谢恩·吉利亚诺 | 2023-03-07 | — | — | CN | claimed |
| CN-115466776-A | Reagent for detecting eosinophils, eosinophils and application of eosinophils, cytoplasmic content of eosinophils and hydroxydocosahexaenoic acid | 中国医学科学院基础医学研究所 | 2022-12-13 | — | — | CN | claimed |
| EP-2405892-B1 | PHARMACEUTICAL FORMULATION COMPRISING KETOPROFEN AND A POLYOXYALKYLENE ESTER OF A HYDROXY FATTY ACID | ADVANCE HOLDINGS LTD (MT) | 2013-01-16 | — | — | EP | claimed |
| EP-2405892-A1 | PHARMACEUTICAL FORMULATION COMPRISING KETOPROFEN AND A POLYOXYALKYLENE ESTER OF A HYDROXY FATTY ACID | Advance Holdings Limited (MT) | 2012-01-18 | — | — | EP | claimed |
| US-20110275717-A1 | PHARMACEUTICAL FORMULATION COMPRISING DICLOFENAC | ADVANCE HOLDINGS LIMITED (MT) | 2011-11-10 | — | — | US | claimed |
| EP-2364140-A1 | PHARMACEUTICAL FORMULATION COMPRISING DICLOFENAC AND A HYDROXY FATTY ACID POLYOXYALKYLENE ESTER | Advance Holdings Limited (MT) | 2011-09-14 | — | — | EP | claimed |
| WO-2010102862-A1 | PHARMACEUTICAL FORMULATION COMPRISING KETOPROFEN AND A POLYOXYALKYLENE ESTER OF A HYDROXY FATTY ACID | ADVANCE HOLDINGS LIMITED (MT) | 2010-09-16 | — | — | WO | claimed |
| WO-2010060798-A1 | PHARMACEUTICAL FORMULATION COMPRISING DICLOFENAC AND A HYDROXY FATTY ACID POLYOXYALKYLENE ESTER | ADVANCE HOLDINGS LIMITED (MT) | 2010-06-03 | — | — | WO | claimed |
| US-20260041696-A1 | IN-SITU PRODUCTION OF ANTI-INFLAMMATORY LIPIDS USING MILK FAT GLOBULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-12 | — | — | US | disclosed |
| EP-3544684-B1 | PERSONALIZED METABOLOMIC PROFILING OF SPECIALIZED PRO-RESOLVING MEDIATORS | BRIGHAM & WOMENS HOSPITAL INC (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2025151582-A1 | SYSTEM AND METHOD FOR BONE MARROW HEMATOPOESIS AND LEUKOCYTE MOBILIZATION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-07-17 | — | — | WO | disclosed |
| CN-115466776-B | Reagent for detecting eosinophils eosinophils and their use of cytosolic contents and hydroxydocosahexaenoic acid | 中国医学科学院基础医学研究所 | 2025-06-27 | — | — | CN | disclosed |
| WO-2004014835-A9 | RESOLVINS: BIOTEMPLATES FOR THERAPEUTIC INTERVENTIONS | BRIGHAM & WOMENS HOSPITAL (US) | 2004-07-08 | — | — | WO | disclosed |
| US-20040116408-A1 | Resolvins: biotemplates for novel therapeutic interventions | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-06-17 | — | — | US | disclosed |
| WO-2004014835-A2 | RESOLVINS: BIOTEMPLATES FOR THERAPEUTIC INTERVENTIONS | BRIGHAM AND WOMEN'S HOSPITAL (US) | 2004-02-19 | — | — | WO | disclosed |
| US-6579720-B1 | By separating into fractions having a predetermined characteristic; comparing the spectral data to identify the data common to the fractions that exhibits the specific characteristic; use in drug screening | BDC PHARMA LLC | 2003-06-17 | — | — | US | disclosed |
| WO-2000070344-A2 | METHOD FOR INCREASING THE EFFICIENCY OF EXPERIMENTAL FRACTIONATION IN ACTIVITY PROFILING OF COMPOUND MIXTURES | ADMETRIC BIOCHEM INC. (US) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041696-A1 | IN-SITU PRODUCTION OF ANTI-INFLAMMATORY LIPIDS USING MILK FAT GLOBULES | ALOX5, ALOX15, ALOX15B | FASN 62/4885ALDH1A1 2772/4885TSHR 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.